Agile Therapeutics, Inc. (AGRX)

Market Cap	5.43M
Revenue (ttm)	19.97M
Net Income (ttm)	8.24M
Shares Out	2.51M
EPS (ttm)	78.17
PE Ratio	0.03
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	22,504
Open	2.09
Previous Close	2.07
Day's Range	2.07 - 2.16
52-Week Range	1.65 - 16.00
Beta	1.81
Analysts	Strong Buy
Price Target	8.50 (+293.52%)
Earnings Date	Nov 9, 2023

About AGRX

Agile Therapeutics, Inc., a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen ...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• IPO Date: May 23, 2014
• Employees: 22
• Stock Exchange: NASDAQ
• Ticker Symbol: AGRX

Financial Performance

In 2022, AGRX's revenue was $10.88 million, an increase of 165.40% compared to the previous year's $4.10 million. Losses were -$25.41 million, -64.24% less than in 2021.

Analyst Forecast

According to 2 analysts, the average rating for AGRX stock is "Strong Buy." The 12-month stock price forecast is $8.5, which is an increase of 293.52% from the latest price.

Price Target

$8.5

(293.52% upside)

Analyst Consensus: Strong Buy